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Introduction
Over decades, billions of dollars have been dedi-
cated to the development of an AIDS vaccine, only
to result in disappointment and failure (1, 2). The
exact number of vaccines tested pre-clinically and
clinically is difficult to determine, but recent
reviews have suggested over 30–40 vaccines in over
85 clinical trials involving almost 20,000 volunteers
(3–7). The US National Institute of Allergy and
Infectious Diseases (NIAID) report over 50 preven-
tive vaccines in over 100 clinical trials (8), and 30-
plus therapeutic trials. This analysis indicates that
the figures are even greater, with no vaccine affect-
ing disease progression (9, 10) or approved for use.
Initial optimism, such as that shown in 1984
when the US Health and Human Services secretary
declared that a vaccine would be available within
two years, has given way to a realisation that the
virus will not be beaten easily. In some quarters, it
is acknowledged that animal models of questionable
relevance are culpable (for comprehensive cited
examples and examples of expert opinion, see [11]
and other cited references throughout this review).
These animal models include the use of macaques
infected with Simian Immunodeficiency Virus (SIV)
or hybrids of SIV and Human Immunodeficiency
Virus (HIV). President Clinton’s 2007 goal for the
development of an AIDS vaccine has now passed,
with notable high-profile failures such as VaxGen’s
AIDSVAX and Merck’s V520 vaccines. In 2004, the
AIDS Vaccine Advocacy Coalition (AVAC) acknowl-
edged that there would be no vaccine available by
2007, foreseeing a ‘long haul’ (12); and optimistic
experts predict that it will be over a decade before
the first vaccine is available — while others predict
half a century (13).
In the light of these statistics and recent high-
profile failures, many scientists are advocating
changes to AIDS vaccine development. A small
number involved in chimpanzee research believe
that chimpanzees have been, and will remain,
important, and thus advocate a return to their use
(14). 
This recommendation requires evidence that
chimpanzees played a crucial role when their use in
the late 1980s and early 1990s was common. This is
the scope of this study: to assess whether their
responses to previous vaccines correlated with
human responses and to compare the immunogenic
and prophylactic natures of those vaccines in chim-
panzees and humans. The a priori argument is that
if the vaccines behaved similarly, the resumed use
of chimpanzees may be scientifically justifiable,
independent of ethical considerations; but if the
chimpanzee results proved erroneously predictive,
there would be no scientific basis upon which to call
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for the reinstatement of chimpanzees in AIDS
research.
Summary of Vaccines and Clinical
Trials
A prerequisite for comparing human and chim-
panzee responses to AIDS vaccines is a comprehen-
sive assessment of which vaccines have been
involved in clinical trials to date. This was achieved
by consulting the National Library of Medicine’s
ClinicalTrials.gov database (http://www.clinicaltri-
als.gov/), for which registration of clinical trials has
been required for several years by the International
Committee of Medical Journal Editors. The search
was performed by using the operators ‘AIDS OR
HIV’ (Disease or Condition field), and ‘Vaccine’
(Experi mental Treatment field). It included all trials
that were no longer recruiting patients. Though
this database may not constitute an exhaustive
repository of information regarding all trials of HIV
vaccines to date, it currently describes around
47,000 trials sponsored by the National Institutes
of Health (NIH), other US federal agencies and pri-
vate industry, conducted in 151 countries. For the
purposes of this investigation, it can be regarded as
the most complete source of HIV clinical trial data
which is readily available. The International AIDS
Vaccine Initiative (IAVI) database (http://www.
iavireport. org/trialsdb/default.asp) was also used to
obtain vaccine details.
All the clinical trials located are summarised in
Table 1. The 197 clinical trials of AIDS vaccines
registered involved 85 different vaccine products
(strain specificity of recombinant proteins, for
example, was taken into account, meaning that
strain MN recombinant gp120 was considered to be
a separate vaccine from strain SF-2 recombinant
gp120).
Figure 1 indicates the types and prevalence of
vaccines tested clinically in the 197 trials: 49 trials
(25%) were of recombinant protein vaccines; 41 tri-
als (21%) were of recombinant microbial vaccines
(RMVs); and 50 trials (25%) used a combination of
two or more approaches. These trials and the others
constituting the remaining 29%, are discussed
below.
Figure 2 provides a breakdown of the types of
vaccines in the RMV class. Of 41 trials, 13 (32%)
involved canarypox vectors, closely followed by ade-
novirus vectors (12 trials [29%]). Eight trials (20%)
were based on vaccinia virus vaccines, and the
remaining 19% involved a variety of viruses and
bacteria, as detailed in the text.
Of the trials, 143 (72%) were Phase I trials
(Figure 3), which involve a relatively small number
of volunteers (typically 20–100) over a two-year
period, in which humans encounter the vaccine for
the first time. Twenty-four (12%) were Phase II tri-
als, in which vaccine candidates that appeared
promising in Phase I investigations are tested in up
to 300 people, including those at high risk of HIV
infection or who are HIV-positive (HIV+). Sixteen
(8%) Phase I/II trials were also registered (i.e.
Phase I and Phase II trials performed in parallel).
Just seven of the 197 clinical trials progressed to
Phase III (the final stage of testing prior to licens-
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Figure 1: AIDS vaccines in clinical trials
A total of 197 trials were registered with ClinicalTrials.gov, up to and including 11 November 2007. 
Mixed = combinations of two or more vaccines; inact. virus = inactivated virus vaccines; rec. protein = recombinant
protein vaccines; VLP = virus-like particles; DNA = DNA-based vaccines; RMVs = recombinant microbial vaccines;
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ing), in which the vaccine is tested typically in up to
3000 people, involving individuals at higher risk. A
further seven trials did not specify the phase.
Figure 4 summarises the status of the registered
trials as of summer 2007. A total of 106 trials (54%)
had reached an end, of which 95 trials (48% of the
total) had been completed, with a further ten ter-
minated and one suspended. Fifty-eight trials (29%)
were ‘no longer recruiting’; 33 were either actively,
or about to begin, recruiting (24 trials and nine tri-
als, respectively).
Detailed Analysis and Human Versus
Chimpanzee Comparison
Vaccines and clinical trials were analysed in detail
to assess whether those that failed in humans pro-
vided protection from HIV infection and/or thera-
peutic benefits in chimpanzees. A comprehensive
analysis was performed of the recent history and
current situation surrounding vaccine development
in chimpanzees (see Table 2 for trial information)
and humans (Table 1), and to compare results and
information from each species. Full use was made of 
the Nonhuman Primate HIV/SIV Vaccine Trials
(NHPVT) Database (http://www.hiv.lanl.gov/content/
vaccine/home.html). In these Tables, the interven-
tions are shown in plain text, underlined, or bold
text, to indicate which specific vaccines were tested
in both species (see Table legends).
Passive approaches
Many of the early experiments in HIV vaccine
research centred on passively transferring HIV and
SIV-specific antibodies from infected to non-
infected animals, to see if this protected the recipi-
ents from infection following a subsequent viral
challenge (for reviews, see 15–19). Five such trials
in chimpanzees are registered in the NHPVT data-
base, and are summarised in Table 2. 
The search of the ClinicalTrials.gov database did
not locate any human trials of passive antibodies to
protect against or to treat HIV infection, but many
reports of pre-clinical and clinical investigations of
passive therapies for HIV/AIDS do exist. The
NHPVT database contains five entries for trials of
this type, and all but the earliest (NHP .361; regis-
tered in 1988) either prevented or controlled HIV
infection in chimpanzees (Table 2). Murthy et al.
(17) referred to passive immunisation studies in
chimpanzees involving a total of five different anti-
bodies. Four of them were protective; the one that
was not protective did, however, delay the onset of
infection (20). HIV human hyperimmune immuno -
globulin (HIVIG) had been shown to protect chim-
panzees from HIV challenge when administered
both pre- and post-exposure (21), an observation
that prompted the authors to conclude that induc-
tion of humoral immunity was a pre-requisite for
any HIV vaccine, but that cell-mediated immunity
may not be needed — a conclusion that is
Role of chimpanzees in AIDS vaccine research                                                                                                                                383
Figure 2: RMV vaccines in clinical trials
Up to and including 11 November 2007, 41 trials involving recombinant microbial vectors were conducted, as 
identified by ClinicalTrials.gov. Multiple = combinations of two or more RMV vaccine types; AAV = adeno-associated















adenovirus AAV vaccinia canarypox VEEA S. typhi
unfounded in humans. Stiehm et al. (22), in con-
trast, assessed the effects of HIVIG in 30 HIV+ chil-
dren, where CD4 cell levels, plasma RNA copy
number, cellular virus load, immunoglobulin levels,
and neutralising antibody titres were only mini-
mally affected and clinical status was not changed. 
A soluble CD4 analogue called ‘CD4-IgG’ (also
known as CD4 immunoadhesin, in which CD4 is
combined with an immunoglobulin for stability)
was also protective in chimpanzee experiments
(23). Trials in humans, however, suggested no evi-
dence of clinical benefit: for example, a Phase I trial
revealed that CD4-IgG did not augment the effects
of the HIV inhibitor drug, azidothymidine (AZT;
24), and a Phase I/II investigation revealed a slight
improvement of T-helper cell function, but no clini-
cal benefit (25). Arguably, these difficulties may be
expected, because HIV+ individuals have high lev-
els of soluble CD4 in their blood, even in quite
advanced AIDS, suggesting it has little or no effect
on progression of the disease.
More recently, Armbruster et al. (26, 27)
described Phase I clinical trials of three human
monoclonal antibodies (hMAbs), in which they were
safe and well tolerated. One of these antibodies had
been shown to delay seroconversion in chimpanzees
some time previously (16), and a paper reported a
proof-of-principle human study (though the evi-
dence is considered to be ‘circumstantial’; 28),
showing that a cocktail of the same hMAbs could
delay viral rebound in HIV-infected patients whose
antiretroviral therapy has been interrupted. There
were major caveats, however: the trial was neither
randomised nor blinded; only two of eight chroni-
cally infected patients showed rebound delay; the
antibodies used had to be highly potent and used at
a high dose; and, there was evidence of rapid escape.
Nevertheless, in spite of these caveats, it is claimed
that the findings from these experiments, in which
the transferred antibodies protected chimpanzees
against HIV-1 infection when administered immedi-
ately prior to or after viral challenge, directed the ini-
tial push toward an HIV vaccine involving
recombinant HIV envelope proteins to induce the pro-
duction of HIV neutralising antibodies (29, 30). The
status of this approach to vaccine development is con-
sidered in detail below (see ‘Recombinant Proteins’).
Attenuated/inactivated virus vaccines
Live attenuated virus vaccines have historically
been used with great success against many diseases
(including measles, mumps and rubella), due to
their induction of strong and broadly reactive
humoral and cell-mediated immune responses (31).
Despite this, putative AIDS vaccines of this class
have been limited to NHP studies and have not
entered clinical trials (32, 33). This is due to con-
cerns over reversion to virulence, recombination
with other virions to form new, potentially highly-
Figure 3: Phases of AIDS vaccine clinical
trials
Percentage of vaccine candidates in different phases of
clinical trials, as of 11 November 2007. 
















phase I phase II phase I/II phase III
Figure 4: Status of AIDS vaccine clinical 
trials
Summary of the status of registered clinical trials of
AIDS vaccines, as of 11 November 2007. 
R/NYR = trials recruiting or not yet recruiting; 
NLR = trials no longer recruiting; C/T/S = completed,
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pathogenic strains, and the dangerous conse-
quences of integration of the attenuated virus
genetic material into the host genome (summarised
by Van der Ryst; 29). Although these concerns are
largely based on the results of macaque experi-
ments, there are convincing human data: immuno-
suppression has occurred in humans exposed to
attenuated HIV via blood transfusions; and residual
infectivity caused over 200,000 people to be infected
by live polio virus during vaccination in the infa-
mous Cutter incident (30).
Inactivated AIDS vaccines, however, have been
tested clinically. Ten trials are registered, including
two in 2005 for the Remune vaccine (formerly
known as HIV-1 Immunogen), which comprises
whole HIV particles that have been chemically and
radioactively inactivated, with their envelopes
removed to preclude the infection of T-cells. The
rationale is to use this vaccine as a therapeutic
intervention, probably in tandem with anti-retrovi-
ral drugs, in people already infected with HIV, in
order to control the activity of the virus by stimu-
lating cell-mediated immunity and thus reduce the
rate of progression of AIDS.
However, Remune has failed to produce promising
results in human subjects. Two of the ten trials (the
most recent of which was registered in 2005) were
terminated, and a large Phase III study failed to find
any additional benefit from Remune, when used to
augment anti-HIV drugs (10). Even more recently in
July 2007, Remune’s manufacturer (Immune
Response Corporation) announced the discontinua-
tion of its HIV Vaccine Development Program alto-
gether, following a disappointing clinical trial of
Remune and its second-generation successor vaccine,
IR103 (consisting of Remune and an adjuvant known
as Amplivax) (34). The results of human trials have
therefore prompted negative opinions concerning this
approach in a number of reviews, for example,
“…inactivated viruses have not been capable of
inducing adequate immunoresponse” (35).
There is evidence of enhanced immune response
in chimpanzees following vaccination with a gp120-
depleted inactivated HIV-1 (36), and the NHPVT
database contained one record of a chimpanzee trial
of this type of vaccine (Table 2). In 1993, inacti-
vated whole HIV-1 was tested along with three dif-
ferent adjuvants (37), in three groups of three
chimpanzees — but even the group with the ‘best’
immune responses became infected when chal-
lenged shortly after their sixth immunisation. It is
therefore assumed that vaccines of this type may
have proceeded to clinical trials based on more-pos-
itive results from experiments with other species.
Recombinant proteins
Immunogenic proteins have constituted a signifi-
cant area of AIDS vaccine research, accounting for
49 (25%) of the 197 registered trials, though just
seven of them have been registered since 2004.
These 49 trials have tested just nine different vac-
cines (or 15 vaccines, if similar proteins from differ-
ent strains of HIV are included). Vaccines tested
have comprised the following: gp160 (expressed in
Vero cells [epithelial cells from African green mon-
keys], in Sf9 cells by using recombinant bac-
ulovirus, and from strains IIIB and LAI-2); gp120
(strains SF2, MN, IIIB, A244 and W61D, and also
Env 2-3 [a yeast-derived gp120 combined with an
adjuvant emulsion]); NefTat fusion protein; Tat
protein; EnvPro (an engineered and stabilised form
of gp160 with adjuvant); and p24 protein (from the
gag gene). Other proteins, such as the viral poly-
merase and regulatory proteins Rev and Vpr, have
also been subject to evaluation. Perhaps the best-
known candidate vaccines from this class are the
AIDSVAX vaccines (AIDSVAX B/B and AIDSVAX
B/E), each comprising two gp120 proteins from dif-
ferent HIV clades.
The relatively high number of trials for the num-
ber of recombinant protein vaccines is due to com-
bination of the immunogenic proteins with a
variety of adjuvants, as well as the testing of dif-
ferent routes of administration. Notably, just nine
of the total of 49 trials have not been completed. Of
the 40 completed trials, just four had progressed
beyond Phase I. Of the nine trials that had not
been completed, three were prematurely termi-
nated. Almost all of the trials (45/49) involved
recombinant envelope protein, since this protein is
the primary target for neutralising antibodies in
infected persons (38). Although invariably
immunogenic, the antibodies induced have tended
to be very clade-specific and have failed to neu-
tralise primary isolates of HIV derived from the
blood of patients. Another major problem with the
use of stand-alone vaccines of this type was quickly
revealed — they rarely induced the cell-mediated
arm of the immune system, which has been
regarded as an essential requirement for an HIV
vaccine for some years (39).
Seven chimpanzee trials of recombinant pro-
teins were listed in the NHPVT database, in
which eight vaccines were tested (Table 2). All
eight tests showed the vaccines to be immuno-
genic (though one test gave mixed results). Three
of the eight tests did not result in protection
(involving two gp120 and one gp160 vaccine),
whereas three tests did result in protection (all of
which involved gp120 vaccines). One of the tests
(with a gp120 vaccine) gave mixed results (where
one animal was protected, but another was not
protected completely), and another test did not
assess protection from infection.
Notable vaccines reported in the scientific litera-
ture include recombinant gp120 vaccines that pro-
tected chimpanzees from subsequent challenge
(40–42), but that failed to show protection in
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human trials (43). The ability of recombinant gp160
protein to confer protection was also shown in
chimpanzees (44, 45), as it was in other studies
where a variety of vaccines were also protective to
chimpanzees, such as whole inactivated virus,
recombinant vaccinia-gp160, the recombinant pro-
teins p18 gag, p27 nef and p23 vif, and peptide
immunogens (46, 47). This protection in chim-
panzees extended to challenge with HIV-infected
lymphocytes, as well as with free virus (48).
Recombinant gp160 protein was also protective in
chimpanzees when boosted with V3 peptides (49,
50).
Also, one of the two aforementioned AIDSVAX
vaccines, produced by VaxGen, was the first candi-
date HIV vaccine to complete a Phase III trial (43),
closely followed by the other. AIDSVAX B/B (com-
prising gp120 envelope proteins from two clade B
strains of HIV, MN and GNE8) failed to protect
more than 5000 trial participants (mainly gay men)
at high risk of HIV infection (51), and AIDSVAX B/E
(comprising gp120 from strains MN and A244 [clade
E]) failed to provide protection against HIV infection
for over 2500 users of injected drugs in Thailand
(52), despite repeated booster immunisations
throughout the study. These failures occurred
despite the fact that AIDSVAX achieved the greatest
immune response of any vaccine of this type (35).
The dearth of active clinical trials of this kind of
vaccine, coupled with high-profile failures, has
prompted some to consider that the concept of the
induction of neutralising antibodies as an HIV vac-
cine strategy has ‘run aground’ (53). Evidence sug-
gests this was recognised by many scientists some
time ago, there having been a distinct re-focusing of
efforts to develop an effective vaccine toward other
approaches, as well as an admission that recombi-
nant proteins could be used only as part of a
‘prime–boost’ vaccine regimen.
Peptide/lipopeptide vaccines
Peptide/lipopeptide vaccines constitute 14 (7%) of
the 197 registered clinical trials, and involve nine
different vaccines. They contain small fragments of
HIV proteins, rather than the complete molecules,
which makes them simpler and cheaper. These
fragments often contain the most immunogenic
parts of the HIV proteins, targeting an immune
response to dominant T-cell epitopes and neutralis-
ing determinants (54), and several peptides from
different strains of HIV can be contained in one vac-
cine. More recently, they have been combined with
lipid molecules to form ‘lipopeptides’, in order to
increase their immunogenicity (55).
In common with recombinant protein vaccines,
most trials of peptides/lipopeptides were registered,
and therefore took place, in and around 1999. Just
four trials have been registered since 2004. All but
one (13/14) of the trials are Phase I trials; the
exception is a Phase II trial of the LIPO-5 vaccine,
which is listed as no longer recruiting participants.
As may be expected due to the lack of trial progres-
sion, and in common with trials of recombinant pro-
tein vaccines, success has not been reported (2, 35,
56, 57), despite, for example, reports of potent and
long-lasting B-cell and T-cell responses to lipopep-
tide immunisation in chimpanzees (58).
No chimpanzee trials of this type of vaccine were
listed in the NHPVT database.
Virus-like particles
Virus-like particles (VLPs, also known as ‘pseudoviri-
ons’) can be generated by the in vitro or in vivo (such
as in transfected cells) production of HIV-1 viral pro-
teins, which can spontaneously assemble into parti-
cles. Only two registered trials were found in
ClinicalTrials.gov, which were both Phase I trials
registered in 1999. One of these (‘HIV-1 Pseudo -
virion’ vaccine) was terminated prior to completion.
Young et al. (31), however, report that the other
vaccine (HIV p17/p24:Ty-VLP) has also been tested
in a Phase II trial (59). In contrast to results
obtained in mice, vaccinated individuals had low
levels of both humoral and cell-mediated immunity.
This vaccine also showed no significant effect on
disease progression in HIV-infected volunteers in a
long-term follow-up study (60). Young et al. (31)
also cite another Phase I trial with VLPp24 vaccine,
which failed to augment immunity to HIV in
infected patients (61). 
No chimpanzee trials of this type of vaccine were
listed in the NHPVT database.
DNA vaccines
Twenty-five (13%) of the 197 registered trials
involved 14 different DNA vaccines, whereby plas-
mids containing HIV genes are used to induce
immunity to the virus when injected intramuscu-
larly. Cells exposed to such plasmids ‘ingest’ the
DNA, which is then transcribed and translated by
the host cells to produce the cognate viral proteins.
When ‘proof of concept’ was initially demonstrated
by injecting DNA into the muscles of mice (62), it
was subsequently shown that proteins produced in
this manner could induce significant humoral and
cellular immune responses (63–65).
The NHPVT database contained three records of
DNA vaccine trials in chimpanzees (NHP .226,
NHP .202 and NHP .71), all of which demonstrated
immunogenicity. One trial provided protection
from HIV infection to an uninfected chimpanzee,
and one vaccine induced an indefinite decrease in
viral load, when used as a therapeutic vaccine for
infected chimpanzees. The other trial was also ther-
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apeutic in nature, and also decreased viral load,
though this effect was transient.
Twenty-five (13%) of the 197 registered trials
examined 14 DNA vaccines. All but three of these
25 trials were Phase I trials, with the remaining
three being Phase I/II trials. Just eight of the 25 tri-
als had been completed at the time of writing, and
one trial of a gag DNA vaccine registered in 2005
has already been terminated.
Many researchers thought that DNA vaccination
would revolutionise vaccine development for many
diseases, not just for HIV. The first human trial
involved HIV-1 strain MN env gp160 and rev genes
(66),  and although marginal increases in anti-gp160
cytotoxic T-lymphocyte (CTL) activity were observed
in a small number of volunteers, there was no
change in CD4+ T-cell count or plasma viral load.
Subsequent trials have continued to fall short: for
example, plasmids encoding nef, tat or env genes
have been only slightly immunogenic (67, 68), and
just three of the trials are anything other than Phase
I trials (i.e. Phase I/II). This disappointment is
reflected in the opinions of authors of several recent
reviews on the topic: “Although immunisation with
DNA plasmids that contain HIV inserts has elicited
substantial cellular responses in mice and nonhu-
man primates, these products have been poorly
immunogenic in humans.” (5); “Plasmid DNA con-
structs have proved to be effective immunogens in
mice for eliciting cellular immune responses and for
priming antibody responses. It is now clear, however,
that DNA vaccines are less immunogenic in non-
human primates than they are in mice, and even less
immunogenic in humans than in non-human pri-
mates.” (69); and “Although DNA vaccines are
immunogenic in mice and monkeys (including
neonates), current vaccines are poorly immunogenic
when administered alone to people.” (70). 
There is ample supporting evidence for such opin-
ions. DNA vaccination has been shown in numerous
studies to produce strong virus-specific immune
responses, and to be protective against HIV infec-
tion in chimpanzees (71–74).
The initial failures with ‘native’ DNA vaccines
have led to efforts to augment vaccine DNA expres-
sion by using co-expressed cytokines (notably inter-
leukin [IL]-12 and IL-15; 5) and adjuvants (55, 75,
76; see Table 1), by improving DNA delivery tech-
niques (77, 78), by using the DNA vaccines in a
combination ‘prime–boost’ approach, and by using
a variety of genetic techniques, such as promoter
modification and codon optimisation (79, 80).
Recombinant microbial vaccines (RMVs)
RMV trials constitute 21% (or 41/197) of all regis-
tered clinical trials, and involve the use of microor-
ganisms that have been genetically engineered to
include HIV genes. Almost all of the vectors are
viral, though the bacterium, Salmonella typhi, has
also been used. The principle involves using the
microorganism to carry the HIV genes into the cells
of the vaccinated individual, where those genes are
expressed and rendered subject to host immune
responses via presentation on the host cell-surface
in association with Major Histocompatibility
Complex (MHC) Class I molecules.
Thirty-seven of the 41 trials have been of indi-
vidual vaccines, and four involved more than one
type of vaccine in this class. Collectively, 24 differ-
ent vaccines have been tested in these trials, with
27 Phase I, 11 Phase II, two Phase I/II and one
Phase III trials initiated. RMVs are a relatively new
approach to the development of an HIV vaccine,
reflected in the fact that just ten clinical trials have
reached a conclusion, and that, excluding the
canarypox class of vaccines, all but one of the trials
were registered in or after 2003. It seems, however,
that the primary emphasis of HIV trials has moved
toward this approach (5), given the recent high pro-
file failures of recombinant-protein vaccines in
Phase III trials, for example (81–83).
Of the concluded trials, seven of the ten were
completed, two were terminated, and one was sus-
pended. 
Adenovirus
Twelve trials involving five adenovirus vaccines
(based on the ‘common cold’ virus) are registered,
constituting 29% of all the trials involving RMVs.
This approach has received much attention, for a
number of reasons: adenoviruses induce mucosal
immunity, which should help prevent HIV infection
at genital/rectal sites; they infect dendritic cells, lead-
ing to the efficient presentation of viral antigens; and
they elicit long-term humoral and cell-mediated
immunity (84). They have also given successful
results, including protection from HIV infection, in
studies in several non-human species, including non-
human primates, for example macaques (85) and
chimpanzees (86–88). A combination approach,
involving recombinant adenovirus-gp160 and gp120
proteins, was also successful in chimpanzees, protect-
ing them from even high-dose challenges of HIV after
only a few immunisations (89–91).
Clinical work in this area is fairly advanced, with
half of these trials being in Phase II, though two of
them have been terminated. These terminated tri-
als involved Merck’s V520 vaccine, which comprises
a recombinant Ad5 adenovirus containing the HIV
gag, pol and nef genes. Despite being widely consid-
ered by experts as “one of the most promising to be
tested on people so far” (92), trials of the vaccine
were terminated in September 2007, when an
interim analysis prior to the planned completion in
2008 concluded that the vaccine simply wasn’t
working. It had failed to protect thousands of 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































volunteers from HIV infection, and also to reduce
HIV levels in people already infected. Disturbingly,
more HIV infections were present in those who had
been given the vaccine, as compared to those given
the placebo (24 versus 21, respectively), with those
who had been in the trial longer and who had
received more injections faring even worse, with 19
cases of HIV infection after vaccination versus just
11 after placebo treatment (93, 94).
As this was the first viral-recombinant vaccine to
reach this stage of clinical trials, and the first to
examine cell-mediated immunity alone in humans
(53), some believe that it raises questions about
whether the use of RMVs can be successful at all,
particularly as vaccines based on adenovirus have
appeared to be the most immunogenic in terms of
the percentage of human responders and the level
and duration of T-cell responses (95).
Adeno-associated virus
Just one trial was identified involving recombinant
adeno-associated virus (AAV), which was registered
in 2007, although it commenced in 2003. This
Phase I trial has been completed, and evaluated an
AAV containing clade C gag, pro, and rt HIV
sequences.
Vaccinia
Of 40 single-intervention recombinant microbial
vaccine trials, eight, involving seven vaccinia-virus
based interventions, were identified, though just
one trial has been completed. All but two are Phase
I trials, with one trial at Phase I/II and another at
Phase II.
Three trials involving recombinant vaccinia vac-
cines in chimpanzees were identified in the NHPVT
database. Although all the vaccines were immuno-
genic, the two trials that took place in the 1980s did
not show protection from HIV infection. The other
trial took place more recently in 2000, but only
assessed immunogenicity.
Modified Vaccinia Ankara virus (MVA) forms the
basis of many recombinant vaccinia approaches to an
HIV vaccine, because of its high degree of attenuation
and consequent good safety profile. Initial results in
human trials, however, have been disappointing, with
cell-mediated immunity being elicited in only a small
minority of individuals (96), despite promising results
in macaques (5). Human trials that include MVA vac-
cines as part of a prime–boost strategy have also been
disappointing (6).
Canarypox
Vectors based on the canarypox virus constitute the
biggest proportion of trials involving RMVs — alto-
gether around a third of the total (13/41, or 32%), five
of which have progressed to Phase II; the remainder
are Phase I trials. These trials involved four different
vaccines, all based upon the ALVAC vector developed
by Sanofi-Pasteur (based on an attenuated strain of
canarypox). In principle, these vectors are highly fit-
for-purpose: they replicate only in the cytoplasm of
infected cells (minimising the risk of integration with
the host genome and any ensuing problems); replica-
tion is restricted; and they are sufficiently safe and
well tolerated in humans (97, 98). Further, they can
accommodate large gene insertions (99), and they can
stimulate both humoral and cell-mediated immune
responses of long duration in humans (100–102).
An early Phase I/II trial ended in disappointment,
however, when a gp160 vaccine (ALVAC-HIV)
failed to enhance both humoral and cell-mediated
immune responses (103). Looking at the register of
clinical trials (Table 1), further failures with other
ALVAC trials appear to have followed. Focus seems
to have shifted to other approaches, signalled by the
low number of trials registered in recent years
(compared to 1999–2001, for example). This is true,
not just for trials solely involving canarypox, but
also for the many trials of AIDS vaccines involving
recombinant canarypox in combination with other
approaches such as the use of DNA and recombi-
nant proteins. In addition, it has been reported that
five different canarypox vaccines have been tested
in around 11,500 volunteers (5). Though well toler-
ated, these vaccines did not induce durable immune
responses, and were immunogenic in fewer than
20% of the subjects (104).
Canarypox vaccines have also been tested in chil-
dren, with similarly disappointing results. For
example, the vCP205 and vCP1452 vaccines were
given to very young infants of HIV+ mothers; again,
they were well tolerated, but produced humoral and
cell-mediated immune responses either not at all, or
of a very low magnitude (105). Comparison with
chimpanzee vaccinations is difficult, as just one
such trial is listed in the NHPVT database, involv-
ing three animals. In this instance, the vCP250 vac-
cine was immunogenic, and protected one of the
two experimental animals from cell-associated viral
challenge. It did not, however, protect this chim-
panzee against subsequent infection with cell-free
HIV (Table 2).
As mentioned previously, many trials have used
canarypox in combination with other vaccine candi-
dates — though this has not resulted in an improve-
ment in efficacy. For example, vCP1452 has been
administered with an AIDSVAX B/B boost to
infants, but enthusiasm for further trials was lim-
ited due to ‘modest immunogenicity’ (70).
Others
Two clinical trials involved the use of Venezuelan
Equine Enceph alitis alphavirus (VEE) as a vector.
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Both Phase I trials, they assessed the vaccine
AVX101, which contains the HIV gag gene as an
immunogen. Another trial, registered in 2003 but
not yet recruiting participants, proposes to evaluate
a vaccine based on recombinant Salmonella typhi
containing the HIV gp120 gene.
Three clinical trials, all registered relatively
recently (2004–2006), involved more than one type
of RMV. Two of the three trials investigated combi-
nations of vaccinia-based (MVA) and fowlpox-based
vaccine pairs, each containing the env/gag and
tat/rev/nef HIV genes. The status of the earlier of
the two trials is ‘no longer recruiting,’ though the
details state that all vaccinations were discontinued
in Novem ber 2006, and the other trial has been sus-
pended. The third trial will assess a ‘prime–boost’
intervention involving an initial DNA plasmid vac-
cine ‘prime’, followed by a Modified Vaccinia
Ankara (MVA) ‘boost’ (this approach is described in
more detail later in this review).
Autologous cells
Dendritic cells are one of the first ports-of-call for
the virus upon infection. They are locally infected
at the entry site of the virus, before proceeding to
the lymph nodes where they infect CD4+ T-cells —
the principal target of the virus, the attrition of
which leads to AIDS. Consequently, dendritic cells
are central to the induction of the immune response
to HIV infection, though their response is known to
decline with time (106–109).
With this in mind, six trials have been registered
that involve two types of autologous-cell approach
to therapeutic HIV vaccination: five with dendritic
cells, and the other with T-cells. The former strat-
egy involves harvesting a patient’s own dendritic
cells and loading them in vitro with HIV peptide
antigens or inactivated autologous virus. The latter
T-cell based vaccine is prepared from autologous T-
cells, which have proliferated following exposure to
recombinant CD4. The cells are then introduced
back into the patient, in the hope that they can bet-
ter activate immune responses that can control the
infection. Early results in humans are considered
promising, at least against the same viral strain
used to produce the cell-based vaccine (110), though
this must be interpreted with caution, as any effi-
cacious vaccine must elicit immune responses
against diverse strains of HIV.
No chimpanzee trials of this vaccine type were
listed in the NHPVT database, though the immuno-
genicity in chimpanzees of dendritic cells pulsed
with test antigens has been reported in the scien-
tific literature, with somewhat equivocal results
(111, 112), and a T-cell vaccine for hepatitis C has
been tested in chimpanzees, which elicited immu-
nity against heterologous hepatitis C virus (HCV;
113).
Multi-component vaccines and prime–boost
strategies
Due to negative results in many trials involving sin-
gle vaccines of all types, much focus has shifted
toward the development of multi-component vac-
cines, in so-called ‘prime–boost’ strategies. This
type of intervention aims to enhance the immune
response to a particular antigen, and to induce both
the humoral and cell-mediated arms of the immune
response by administering it in successive, but
slightly different, ways — especially when using
just one route/vaccine type has not proved suffi-
ciently immunogenic. The rationale is to ‘prime’ the
immune system with the first antigen (for example,
a DNA vaccine or recombinant adenovirus or
poxvirus), and then to ‘boost’ the immune response
to it by using, for example, another RMV or protein. 
Fifty clinical trials were identified in this category
(Figure 5), with the most prevalent combinations
being canarypox–protein (15 trials), adenovirus–DNA
(11 trials) and vaccinia–protein (7 trials). Given the
relatively recent nature of this type of approach, the
majority of the trials are Phase I trials (31/50), with
just seven Phase II and two Phase III trials. One of
the Phase II trials, involving a canarypox–lipopeptide
vaccine (ALVAC HIV-1433 and LIPO-6T), was termi-
nated, and a recent publication revealed that HIV-
specific CD4+ T-cell responses did not change in
immunised patients relative to controls, that the vac-
cination had only a transient effect on interferon-
gamma-producing CD8 responses, and that the viral
rebound after treatment interruption was similar in
immunised patients and controls (114). The Phase III
trial, involving a canarypox–inactivated virus vaccine
(vCP1452 and Remune), was registered in 2000 and
has been completed (without success), and the other
trial, involving a canarypox–protein vaccine combina-
tion (vCP1521 and AIDSVAX gp120 B/E), com-
menced in 2003 and is no longer recruiting.
Despite this Phase II termination and the lack of
reported success surrounding the Phase II trials,
much hope is held in some quarters for this strat-
egy, largely based on pre-clinical studies in mon-
keys, where prime–boost vaccines are often more
potent than either vaccine alone (55). The NHPVT
database lists four chimpanzee trials of multi-com-
ponent vaccines, one of which tested two different
vaccine combinations. All five combinations were
immunogenic. One of the trials (NHP .465), involv-
ing an adenovirus prime and an oligomeric gp140
boost, did not assess protection from infection, but
all the other vaccines demonstrated protection,
except one, which comprised a vCP125/gp160 com-
bination (trial NHP .167). In addition to those stud-
ies registered with the NHP database, Girard et al.
(47) reported the protection of chimpanzees from
HIV infection following immunisation with “a vari-
ety of HIV-1 immunogens — followed by rgp160
and V3 peptides”, including combinations of enve-
Role of chimpanzees in AIDS vaccine research                                                                                                                                417


















































































































































































































































































































































































































































































































































































































































































































lope antigens. This all contrasts with findings in
humans, however, where “observations in early
phase clinical trials in humans have not been prom-
ising”, due to adverse reactions and lack of diversity
in the immune response (115). 
Naturally, not all the vaccines tested in chim-
panzees have provided protection against HIV chal-
lenge. One of the vaccine combinations tested by
Girard et al. (47), for example, described a combi-
nation strategy involving recombinant gp160–
canarypox and recombinant gp160 protein, that
failed, although the low dose of the vaccine was pos-
tulated as a factor.
Summary and Discussion
To date, 85 candidate AIDS vaccines have been
tested in 197 clinical trials, comprising several main
types — from inactivated virus vaccines through
DNA plasmids to recombinant proteins and viruses.
Just 12% of these trials have reached Phase II, only
seven (3.5%) have reached Phase III, and alto-
gether, 18 trials were prematurely terminated.
None has been successful.
Early optimism has transformed into a realisa-
tion that we are decades away from even a partially
effective vaccine in humans. The monumental
financial and human resources allocated to vaccine
development have resulted in dozens of safe and
effective vaccines only for chimpanzees and mon-
keys with laboratory-induced infections. Hope that
the use of NHPs will lead to the successful develop-
ment of a vaccine for humans is tempered by the
recent, high-profile failures of the AIDSVAX and
V520 (Merck) candidates in extensive and late-stage
clinical trials. Notably, the latter increased the risk
of HIV infection compared to the placebo — and it
is not alone in this respect: previously, gp120-based
vaccines increased the risk that vaccinated people
would develop an infection or progress to AIDS
post-infection (116).
Furthermore, the limited critical appraisal to date
of the favoured SIV/chimeric SIV–Human Immuno -
deficiency Virus (SIV/SHIV)-macaque model, has
been unfavourable (35, 53, 56, 117–121), stimulating
a desire for models of greater relevance. While some
scientists associated with chimpanzee research advo-
cate a resumption of their use, such use must be
objectively and independently evaluated.
Poor performance of the chimpanzee model
in the development of AIDS vaccines
This analysis expands on previous data that under-
lined the poor performance of chimpanzees as mod-
els in HIV/AIDS research, evidenced by a large
number of negative opinions and comments toward
it and by the significant withdrawal of NIH funding
for it. The evidence provided, based on a compari-
son of human and chimpanzee responses to AIDS
vaccines, gives further argument against a return
to chimpanzee-use in this field.
Contrary to claims that chimpanzees play a “crit-
ical role in the testing of potential [HIV] vaccines”
and that they “are still important for testing vac-
cines aimed at preventing HIV-1 infection or reduc-
ing the virus load in infected individuals”(14), this
review shows that neither claim has any scientific
foundation. Many vaccines of many types have been
tested in chimpanzees prior to clinical trials, and
their correlation to, and predictive nature for, the
human response is demonstrably poor. Chimp -
anzees have been protected from HIV infection pas-
sively via the transfer of antibodies (both pre- and
post-exposure), which prompted the (now highly
unlikely) suggestion that cell-mediated immunity is
not necessary. Passive protection has also been
induced by a soluble CD4 analogue. Neither
approach has been successful in humans. Atten -
uated vaccines have provided protection in chim-
panzees, but have not been tested clinically due to
safety concerns. Inactivated-virus vaccines have
disappointed clinically, and while results were sim-
ilarly negative in chimpanzees, these results were of
little relevance and did not prevent inactivated-
virus vaccines from progressing to clinical trials.
Negative results with recombinant protein vaccines
in chimpanzees (Table 2) also did not stop these
vaccines progressing to further testing and clinical
trials (122).
While RMVs have been disappointing in humans,
including the Phase III AIDSVAX trials, many
(excluding a couple of early efforts) provided protec-
tion from HIV infection in chimpanzees. Clinical trial
success with peptide and lipopeptide vaccines has not
been reported, despite prior evidence of potent and
persistent cell-mediated immune responses in chim-
panzees. Both preventive and therapeutic DNA vacci-
nation have been successful in chimpanzees.
Optimism for success in humans was high, but poor
immunogenicity has led to recent disparaging com-
ments. Recombinant adenovirus vaccines have
elicited protection from HIV infection in chim-
panzees, both alone and in combination with recom-
binant HIV proteins. However, the situation in
humans may be grave, with possibly “the most prom-
ising [vaccine] tested on people so far”, in the form of
Merck’s V520 vaccine, not only ending in the termi-
nation of its Phase IIb trial, but increasing the risk of
HIV infection for its recipients.
Due to the diminished use of chimpanzees in
pre-clinical testing for reasons discussed above,
some types of vaccines have not been widely tested
in chimpanzees. Immunogenicity has been demon-
strated in chimpanzees with vaccinia-based vac-
cines, however — which is true in only a small
minority of humans in clinical trials so far.
Similarly, canarypox vaccines have induced pro-
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tection from cell-associated (but not cell-free)
virus challenge in chimpanzees, but several vec-
tors have been immunogenic in a small proportion
of clinical-trial volunteers, including children,
even as part of prime–boost regimens — and then
only poorly so. Some prime–boost vaccines, involv-
ing a variety of immunogens, have proven positive
in chimpanzees, again in contrast to humans, in
which the results have been disappointing, replete
with adverse reactions and lack of diversity in the
immune response.
Problems with the chimpanzee model:
Reasons for its lack of relevance
Researchers continue to rely on results largely from
macaques infected with SIV or SHIV (an SIV/HIV
hybrid), despite important differences between SIV-
infected macaques and HIV-infected humans (53,
117). Significant disparities exist in virulence,
pathology, genetics, protein function, infection and
host response (118). Two recent reviews stated
that, “efficacy of HIV-1 based vaccines cannot be
directly evaluated in the SIV model” (119) and that,
“this has not proven a practical animal model for
studying vaccines” (35), the latter citing significant
supporting evidence (56, 121, 122). A 2007 review
stated, “When it comes to testing HIV vaccines,
only humans will do” (53); another cited, “the per-
sistent view held by many that there is no predic-
tive animal model for HIV infection in humans”
(123), and another that, “No animal models faith-
fully reproduce... HIV-1 infection and disease in
humans, and the studies of experimental vaccines
in animal models... have yielded disparate results”
(124).
Yet the rhesus macaque became the model of
choice following the discovery in 1987 that SIV
caused an AIDS-like disease in these animals (125).
It replaced the chimpanzee, widely used in AIDS
research for several years previously but which had
“had problems from the get-go” (125) — vis-à-vis
practicality (the significant costs of using and main-
taining chimpanzees, including user’s fees of
$50,000+ per animal), statistical significance (few
animals could be used in each experiment, giving
unreliable results), and species differences (HIV
infection rarely progresses to AIDS-like illness in
chimpanzees) “undermining the model’s reliabil-
ity” (125). The latter problem of scientific unrelia-
bility is, from a human perspective, most worrying.
If years of chimpanzee use in HIV/AIDS research
have not led to tangible progress and improvements
clinically, then they represent a waste of limited
resources and have done little to alleviate human
suffering, as there is still no AIDS vaccine and none
is imminent. A brief summary of the known differ-
ences between human and chimpanzee HIV infec-
tion and ensuing pathology may explain why.
Chimpanzees have higher baseline levels of CD8+
T-cells and a higher ratio of CD8+/CD4+ T-cells,
and their percentage of beta-chemokine-positive
CD8+ T-cells and natural killer (NK) cells is signif-
icantly higher than in uninfected humans.
Chimpanzees do not typically produce increased
numbers of these cells following HIV infection,
unlike humans (126). As these are the cells that
attempt to control infection, and the latter are the
cells infected by HIV-1 and subsequently destroyed
by the virus, this is critical. Unlike in humans, it is
difficult to routinely isolate HIV from the plasma
and sera of infected chimpanzees (127), and chim-
panzee CD4+ cell numbers do not drop dramatically
over the course of HIV infection, with remarkably
few exceptions. Instead, detectable plasma HIV
decreases and eventually becomes undetectable
(117). With perhaps only one exception, HIV infec-
tion of chimpanzees does not result in a significant
decline in CD4+ T-cell levels, immunodeficiency
and AIDS-like illness, as in humans. The exception
was Jerom (‘Chimpanzee C499’), who was infected
with three different isolates of HIV-1 over ten years
and suffered a progressive decline in CD4+ T-cells
and developed AIDS-like symptoms, caused by a
quasispecies of HIV that had mutated to become
more pathogenic (128). Notably, Jerom’s blood,
though it caused a similar decline in CD4+ T-cells
in other chimpanzees transfused with it, did not
cause them to develop a similar disease (129).
These differences, difficulties, and the lack of a
vaccine led many scientists to conclude that chim-
panzees should have no place in the quest for an
AIDS vaccine. In 1994, the Handbook of Laboratory
Animal Science called primate models of AIDS
“unsuccessful” (130). The NIH AIDS Research
Program Evaluation Task Force cited the “limited
utility of the chimpanzee model” and recommended
“redirecting monies currently expended in the less
relevant chimpanzee model” (131). The latter was
put into practice: AIDS-related chimpanzee studies
fell from almost 30 studies in 1998 to four in 2005.
Thomas Insel M.D., former director of the Yerkes
Regional Primate Center, noted that 15 years of
work in chimpanzees has produced little data rele-
vant to humans, stating “I can’t tell you what it is
that those [chimpanzee] studies have given us that
has really made a difference in the way we approach
people with this disease [HIV/AIDS]” (132); and a
review article in 2000 opined “Defending the use-
fulness of the chimpanzee as a model for HIV
research has not only become a difficult task, but
also a controversial one” (133).
These realisations came too late. At least 198
chimpanzees were deliberately infected with HIV
prior to 1997 (134), and around 1,300 chimpanzees
are currently in US laboratories, due in large part
to over-breeding for AIDS research in anticipation
of their use in this area, and despite a breeding
moratorium being in place for the past decade.
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Ethical issues associated with chimpanzee use
Ethics must be considered alongside scientific rele-
vance, because of the cost of chimpanzee use, and
because chimpanzees are a ‘special case’, testified to
by public and scientific opinion, and policies and
laws in the US and throughout the world. The pas-
sage of the CHIMP (Chimpanzee Health Improve -
ment, Maintenance and Protection) Act in the USA
in 2000, as well as the fact that many countries ban
or restrict the use of great apes, acknowledges a dif-
ferent moral status for chimpanzees. Both scien-
tists and the public acknowledge that chimpanzees
have advanced cognitive abilities, and social and
emotional needs. They are capable of reasoned
thought, abstraction, generalisation and symbolic
representation; have a concept of self; exhibit a
broad range of emotions; experience mental as well
as physical pain; and can be taught to communicate
in human languages such as American Sign Lang -
uage, and demonstrate complex nonverbal commu-
nication patterns among themselves (135–142). In
captivity, they show a range of behavioural abnor-
malities and measurable signs of distress (psy-
chopathology; 143, 144). The widely-respected
researcher and advocate for chimpanzee welfare,
Jane Goodall, stated in a letter to Science that, “It
is their humanlike behaviours that most fascinate
people: their tool-using and making abilities, the
close supportive bonds among family members…
and their complex social interactions — the cooper-
ation, the altruism, and the expression of emotions
like joy and sadness” (145). 
Conclusions
The evidence presented in this study includes: 
— substantial differences between chimpanzee and
human responses to HIV infection and the
course of the disease; 
— expert opinion; 
— past failures as a vaccine model; 
— progression of vaccines to clinical trials despite
negative results in chimpanzees; 
— increasing knowledge of chimpanzees’ cognitive
and emotional capacities; and 
— increased ethical issues surrounding chim-
panzee research.
From this evidence, it is concluded that chim-
panzees have no justifiable role in AIDS vaccine
research and testing. Advocating the resumption of
their use defies the burden of scientific evidence of
repeated failures involving their use. If chim-
panzees were not reliable, predictive and fit for pur-
pose from 1990 to 2008, what justification is there
for a resumption of their use? A 2006 review of
AIDS vaccine testing, when referring to chim-
panzee trials of inactivated-virus and DNA vac-
cines, concluded “it proved difficult to examine the
effect of these vaccines, due to the general lack of
clinical progression to immunodeficiency in this
animal model and the prohibitive cost of these
experiments” (7). 
Some twenty years after chimpanzees were the
mainstay of AIDS vaccine testing, an efficacious
vaccine for human use remains unavailable and not
imminent. The use of chimpanzees has largely been
abandoned for scientific and cost–benefit reasons.
As millions of humans continue to become infected
or die each year, the continued use of chimpanzees
in AIDS research is scientifically unwise and ethi-
cally unjustifiable.
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